Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Jonathan Monson - Executive VP & CFO Ken Stein - Senior VP & Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Michael Polark - Wolfe Research, LLC Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Christopher Pasquale - Nephron Research LLC Pito Chickering - Deutsche Bank AG, Research Division Presentation Operator Good morning, and welcome to the Boston Scientific Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Boston Scientific (BSX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Boston Scientific (BSX) Q3 Earnings and Revenues Top Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.63 per share a year ago.
Beware The Death Cross: 3 Stocks Triggering This Spooky Signal
There are two types of Halloween people: those who like jump scares and those who don't. But even if you're a fan of haunted hayrides and movies like The Conjuring, you probably don't want to ever get a jump scare from your portfolio, which is why so many investors use diversified index funds with the bulk of their wealth.
Unlocking Q3 Potential of Boston Scientific (BSX): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Boston Scientific buys Nalu Medical for $533 million
Medical device maker Boston Scientific said on Friday it will buy privately-held Nalu Medical for a cash payment of about $533 million, expanding its portfolio to address chronic pain.
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
4 Top AI-Powered Healthcare Stocks
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasingly deploying AI in drug discovery, diagnostics, imagery, robot-assisted surgery, and hospital administration.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.
Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript
Boston Scientific Corporation (NYSE:BSX ) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Arthur Butcher - Executive VP and Group President of MedSurg & Asia Pacific Jim Cassidy Meghan Scanlon Adam Smith Brian Dunkin Joseph Fitzgerald - Executive VP & Group President of Cardiology Peter Pattison - President of the Interventional Oncology Division Catherine Jennings Lance Bates Janarthanan Sathananthan - Chief Medical Officer of Interventional Cardiology Therapies Scott Olson Ken Stein - Senior VP & Global Chief Medical Officer Angelo De Rosa Brad Sutton Nicholas Spadea-Anello Jonathan Monson - Executive VP & CFO Conference Call Participants Joanne Wuensch - Citigroup Inc., Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Pito Chickering - Deutsche Bank AG, Research Division Travis Steed - BofA Securities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Michael Polark - Wolfe Research, LLC Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Matson - Needham & Company, LLC, Research Division Marie Thibault - BTIG, LLC, Research Division Matthew Taylor - Jefferies LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Richard Newitter - Truist Securities, Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Conversation Operator Please welcome Lauren Tengler.
